Holmes, Frankie Ann <br/><br/>
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.  [electronic resource] 

 -  BMC research notes  Dec 2013 
 - 507 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1756-0500 
<br/><br/><label>Standard No.: </label>10.1186/1756-0500-6-507  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Autophagy<br/>Biomarkers, Pharmacological<br/>Breast Neoplasms--drug therapy<br/>Carcinoma, Ductal, Breast--drug therapy<br/>Drug Administration Schedule<br/>Female<br/>Forkhead Box Protein O1<br/>Forkhead Transcription Factors--genetics<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Lapatinib<br/>Middle Aged<br/>Neoadjuvant Therapy--methods<br/>PTEN Phosphohydrolase--genetics<br/>Paclitaxel--administration & dosage<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Phosphorylation<br/>Quinazolines--administration & dosage<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>STAT5 Transcription Factor--genetics<br/>Signal Transduction--drug effects<br/>Trastuzumab